European Union antitrust regulators will decide by December 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer Catalent. Catalent posted a surprise first-quarter loss and ...

Novozymes and Chr. Hansen have historically generated ample free cash flow and returned value to shareholders primarily through dividends. Management expects to continue to reward shareholders with a ...

Dr Olale's leadership at MedGenome will accelerate the company’s transformation into the preferred partner for academic institutions, biopharma, and biotech companies seeking advanced multiomic and ...

Canada Goose Holdings , beat Wall Street estimates for quarterly revenue on Thursday, as steady demand for its pricey puffer ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Treace Medical Concepts (TMCI – Research Report), ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Shares of several bitcoin-related companies, including trading app Robinhood (HOOD), cryptocurrency exchange Coinbase Global (COIN) and Marathon Digital parent company MARA Holdings (MARA ... $6 ...

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...

Novo Holdings planned $16.5 billion purchase of Catalent (NYSE:CTLT) is being probed by the European antitrust regulator. The European Commission has set a date of Dec. 6 to decide if its analysis of ...